Progress of ulcerative colitis patients during the COVID-19 pandemic

doi:10.12998/wjcc.v11.i23.5462

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 23

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2303)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

112

WORD

HTML

958

Figures (1-1)

167

Tables (1-2)

173

Sum=1433

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

178

Download

604

Sum=782

Aug 16, 2023 (publication date) through Oct 2, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Aug 16, 2023; 11(23): 5462-5467
Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5462

Table 2 Pharmacotherapies used for the 2020, 2021, and 2022 groups, n (%)

	2020 (n = 289)	2021 (n = 279)	2022 (n = 268)
5-ASA	165 (57.0)	158 (56.6)	151 (56.3)
AZA or 6-MP	35 (12.1)	32 (11.4)	33 (12.3)
IFX	36 (12.4)	35 (12.5)	33(12.3)
ADA	26 (8.9)	26 (9.3)	26 (9.7)
GLM	9 (3.1)	9 (3.2)	7 (2.6)
VDZ	0 (0)	1 (0.3)	1 (0.3)
UST	0 (0)	1 (0.3)	1 (0.3)
TFN	2 (0.6)	2 (0.7)	3 (1.1)
TF	8 (2.7)	8 (2.8)	7 (2.6)
IR	5 (1.7)	5 (1.7)	4 (1.0)
PSL	1 (0.3)	0 (0)	1 (0.3)
CHM	1 (0.3)	1 (0.3)	1 (0.3)
ND	1 (0.3)	1 (0.3)	0 (0)

5-ASA: Aminosalicylic acid; AZA: Azathioprine; 6-MP: Mercapton; IFX: Infliximab; ADA: Adalimumab; GLM: Golimumab; UST: Ustekinumab; TFN: Tofacitinib; VDZ: Vedolizmab; TF: Topical formulation; IR: Intestinal regulator; PSL: Prednisolone; CHM: Chinese herbal medicine; ND: No drug.

Citation: Suda T, Takahashi M, Katayama Y, Soga K, Kobori I, Kusano Y, Tamano M. Progress of ulcerative colitis patients during the COVID-19 pandemic. World J Clin Cases 2023; 11(23): 5462-5467
URL: https://www.wjgnet.com/2307-8960/full/v11/i23/5462.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i23.5462